Oral Drug Delivery Mechanism

Enteris BioPharma’s clinically proven, cutting edge oral drug delivery technology, Peptelligence®, enables the oral delivery of molecules that are typically injected, including peptides and BCS Class II, III, and IV small molecules, in an enteric-coated tablet formulation.

Enteris’ formulation technology is made up of two key components, the first is a permeation enhancer, which loosens tight junctions in the intestinal enterocytes and allows paracellular transport. The permeation enhancer, a surfactant, also acts as a great solubilizing agent. The other main excipient, citric acid, also plays an active, multifunctional role in transport by acting as a calcium chelator and membrane permeation enhancer, a pH-lowering agent that increases absorptive flux, and a membrane wetting/charge dispersal agent.

Enteris has demonstrated its ability to effectively deliver a variety of molecules across multiple therapeutic indications.

Download Peptelligence® Brochure        OR        Contact Us

Oral Drug Delivery Mechanism

Enteris BioPharma mechanism for oral drug delivery example

(Click on image to enlarge)

   Clinical Trial Manufacturing Offerings

Several clinical studies have been carried out with peptides utilizing the Enteris’ technology.

  • Positive Phase 3 oral Calcitonin: Osteoporosis
  • Positive Phase 2 oral PTH: Osteoporosis
  • Positive Phase 2 oral Calcitonin: Osteopenia
  • Positive Phase 2b oral CR845: Neuropathic Pain

Phase 2 Results: PK Profile for PTH

Enteris BioPharma Phase 2 results chart

(Click on image to enlarge)

The Enteris BioPharma formulation technology is a simple, elegant, and scalable solution designed to overcome previously unmet challenges in both permeability and solubility, with a demonstrated track record of clinical success across a range of compounds and therapeutic indications.